Salarius Pharmaceuticals, Inc. Gains 63.55%

Salarius Pharmaceuticals, Inc. (SLRX:NASDAQ) rocketted at $3.5, a gain of 63.6%. On Thu, Jul 25, 2024, SLRX:NASDAQ hit a New 2-Week High of $3.5. From Thu, Jul 11, 2024, the stock recorded 30.00% Up Days and 27.27% Green Days

The stock spiked on Tue, Jul 23, 2024 at $7.2 with a volume of 59M+.

About Salarius Pharmaceuticals, Inc. (SLRX:NASDAQ)

Flex Pharma Inc is a US-based biotechnology company which is engaged in the developing proprietary treatments for muscle cramps and spasms associated with severe neurological conditions and exercise-associated muscle cramps. The lead drug product candidate is FLX-787 which is a single molecule, chemically synthesized, TRP ion channel activator and HOTSHOT, which is developed to prevent and treat exercise-associated muscle cramps. It operates through two segments - Consumer Operations and Drug Development. The Consumer Operations segment includes the development of HOTSHOT whereas the Drug Development segment includes the development of proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions.